{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T02:12:08Z","timestamp":1772244728403,"version":"3.50.1"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>\n                    The sudden rise of the SARS-CoV-2 virus and the delay in development of effective therapeutics for mitigation made evident a need for ways to screen compounds that can block infection and prevent further pathogenesis and spread. However, identifying effective drugs that are efficacious against viral infection and replication with minimal toxicity for the patient can be difficult. Monoclonal antibodies were shown to be effective, but as the SARS-CoV-2 mutated, these antibodies became ineffective. Small-molecule antivirals were identified using pseudovirus constructs to recapitulate infection in nonhuman cells, such as Vero E6 cells. However, the impact was limited due to poor translation of these compounds in the clinical setting. This is partly due to the lack of similarity of screening platforms to the\n                    <jats:italic>in vivo<\/jats:italic>\n                    physiology of the patient and partly because drugs effective\n                    <jats:italic>in vitro<\/jats:italic>\n                    showed dose-limiting toxicities. In this study, we performed two high-throughput screens in human lung adenocarcinoma cells with authentic SARS-CoV-2 virus to identify both monoclonal antibodies that neutralize the virus and clinically useful kinase inhibitors to block the virus and prioritize minimal host toxicity. Using high-content imaging combined with single-cell and multidimensional analysis, we identified antibodies and kinase inhibitors that reduce viral infection without affecting the host. Our screening technique uncovered novel antibodies and overlooked kinase inhibitors (i.e., PIK3i, mTORi, and multiple RTKi) that could be effective against the SARS-CoV-2 virus. Further characterization of these molecules will streamline the repurposing of compounds for the treatment of future pandemics and uncover novel mechanisms viruses use to hijack and infect host cells.\n                  <\/jats:p>","DOI":"10.3389\/fcell.2025.1538934","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T01:25:26Z","timestamp":1747877126000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cell-based high-content approach for SARS-CoV-2 neutralization identifies unique monoclonal antibodies and PI3K pathway inhibitors"],"prefix":"10.3389","volume":"13","author":[{"given":"Carly R.","family":"Cabel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Briana A.","family":"Guzman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaheh","family":"Alizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuaizhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cameron","family":"Holberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chonlarat","family":"Wichaidit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darren A.","family":"Cusanovich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew L.","family":"Paek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory R. J.","family":"Thatcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koenraad","family":"Van Doorslaer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel S.","family":"Nargi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel E.","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naveenchandra","family":"Suryadevara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"James E.","family":"Crowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert H.","family":"Carnahan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel K.","family":"Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Curtis A.","family":"Thorne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/S1473-3099(23)00011-7","article-title":"Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study","volume":"23","author":"Aggarwal","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.3390\/v13122434","article-title":"Propagation of SARS-CoV-2 in calu-3 cells to eliminate mutations in the furin cleavage site of spike viruses 13","volume":"13","author":"Baczenas","year":"2021","journal-title":"Viruses"},{"key":"B5","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.drudis.2021.11.002","article-title":"The PI3K\/Akt\/mTOR pathway: a potential pharmacological target in COVID-19","volume":"27","author":"Basile","year":"2022","journal-title":"Discov. Today"},{"key":"B6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nbt.4314","article-title":"Dimensionality reduction for visualizing single-cell data using UMAP","volume":"37","author":"Becht","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1017\/s1355838200992318","article-title":"Determination of preferential binding sites for anti-dsRNA antibodies on double-stranded RNA by scanning force microscopy","volume":"6","author":"Bonin","year":"2000","journal-title":"RNA"},{"key":"B8","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"R100","DOI":"10.1186\/gb-2006-7-10-r100","article-title":"CellProfiler: image analysis software for identifying and quantifying cell phenotypes","volume":"7","author":"Carpenter","year":"2006","journal-title":"Genome Biol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"109604","DOI":"10.1016\/j.celrep.2021.109604","article-title":"Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals","volume":"36","author":"Chen","year":"","journal-title":"Cell Rep."},{"key":"B11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJMoa2029849","article-title":"SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with covid-19","volume":"384","author":"Chen","year":"","journal-title":"N. Engl. J. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s41423-020-0426-7","article-title":"Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor","volume":"17","author":"Chen","year":"2020","journal-title":"Mol. Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.1016\/j.cell.2021.05.005","article-title":"Tackling COVID-19 with neutralizing monoclonal antibodies","volume":"184","author":"Corti","year":"2021","journal-title":"Cell"},{"key":"B14","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13073-020-00763-0","article-title":"Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein","volume":"12","author":"Davidson","year":"2020","journal-title":"Genome Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"108959","DOI":"10.1016\/j.celrep.2021.108959","article-title":"Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2","volume":"35","author":"Dittmar","year":"2021","journal-title":"Cell Rep."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1038\/s41564-021-00972-2","article-title":"Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail","volume":"6","author":"Dong","year":"2021","journal-title":"Nat. Microbiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s12026-022-09268-x","article-title":"PI3K\/Akt\/mTOR pathway: a potential target for anti-SARS-CoV-2 therapy","volume":"70","author":"Fattahi","year":"2022","journal-title":"Immunol. Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.3390\/v14091999","article-title":"A critical analysis of the use of cilgavimab plus tixagevimab monoclonal antibody cocktail (Evusheld) for COVID-19 prophylaxis and treatment viruses 14","volume":"14","author":"Focosi","year":"2022","journal-title":"Viruses"},{"key":"B19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41541-021-00346-z","article-title":"A cautionary perspective regarding the isolation and serial propagation of SARS-CoV-2 in Vero cells","volume":"6","author":"Funnell","year":"2021","journal-title":"NPJ Vaccines"},{"key":"B20","doi-asserted-by":"publisher","first-page":"A1","DOI":"10.1016\/j.jor.2021.01.011","article-title":"What is the difference between the first and the second\/third wave of Covid-19? - German perspective","volume":"24","author":"Graichen","year":"2021","journal-title":"J. Orthop."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.3201\/eid2606.200516","article-title":"Severe acute respiratory Syndrome coronavirus 2 from patient with coronavirus disease, United States","volume":"26","author":"Harcourt","year":"2020","journal-title":"Emerg. Infect. Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e0247321","DOI":"10.1128\/mBio.02473-21","article-title":"A combination of receptor-binding domain and N-terminal domain neutralizing antibodies limits the generation of SARS-CoV-2 spike neutralization-escape mutants","volume":"12","author":"Haslwanter","year":"2021","journal-title":"mBio"},{"key":"B23","doi-asserted-by":"publisher","first-page":"100735","DOI":"10.1016\/j.xcrm.2022.100735","article-title":"Remdesivir-induced emergence of SARS-CoV2 variants in patients with prolonged infection","volume":"3","author":"Heyer","year":"2022","journal-title":"Infect. Cell Rep. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B25","doi-asserted-by":"publisher","first-page":"110559","DOI":"10.1016\/j.biopha.2020.110559","article-title":"Targeting SARS-CoV2 spike protein receptor binding domain by therapeutic antibodies","volume":"130","author":"Hussain","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"B26","doi-asserted-by":"publisher","first-page":"W739","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e00819","DOI":"10.1128\/AAC.00819-20","article-title":"Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs","volume":"64","author":"Jeon","year":"2020","journal-title":"Agents Chemother."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.3346\/jkms.2021.36.e124","article-title":"Will mutations in the spike protein of SARS-CoV-2 lead to the failure of COVID-19 vaccines?","volume":"36","author":"Jia","year":"2021","journal-title":"J. Korean Med. Sci."},{"key":"B29","article-title":"COVID-19 dashboard by the center for systems science and engineering (CSSE)","year":"2020"},{"key":"B30","doi-asserted-by":"publisher","first-page":"5129","DOI":"10.1080\/07391102.2020.1784291","article-title":"Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease","volume":"39","author":"Kandeel","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.bmc.2011.12.021","article-title":"Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802)","volume":"20","author":"Kinoshita","year":"2012","journal-title":"Bioorg Med. Chem."},{"key":"B32","doi-asserted-by":"publisher","first-page":"101497","DOI":"10.1016\/j.tice.2021.101497","article-title":"Clinically relevant cell culture models and their significance in isolation, pathogenesis, vaccine development, repurposing and screening of new drugs for SARS-CoV-2: a systematic review","volume":"70","author":"Kumar","year":"2021","journal-title":"a Syst. Rev. Tissue Cell"},{"key":"B33","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2144\/000112257","article-title":"CellProfiler: free, versatile software for automated biological image analysis","volume":"42","author":"Lamprecht","year":"2007","journal-title":"Biotechniques"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e2022643118","DOI":"10.1073\/pnas.2022643118","article-title":"SARS-CoV-2 induces double-stranded RNA-mediated innate immune responses in respiratory epithelial-derived cells and cardiomyocytes","volume":"118","author":"Li","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e2113401118","DOI":"10.1073\/pnas.2113401118","article-title":"Targeting the coronavirus nucleocapsid protein through GSK-3 inhibition","volume":"118","author":"Liu","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B36","doi-asserted-by":"publisher","first-page":"521","DOI":"10.2217\/imt-2022-0027","article-title":"Blocking EGFR with nimotuzumab: a novel strategy for COVID-19 treatment","volume":"14","author":"Londres","year":"2022","journal-title":"Immunotherapy"},{"key":"B37","doi-asserted-by":"publisher","first-page":"5981","DOI":"10.1158\/1078-0432.CCR-17-0725","article-title":"A first-time-in-human study of GSK2636771, a phosphoinositide 3 kinase beta-selective inhibitor, in patients with advanced solid tumors","volume":"23","author":"Mateo","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12985-022-01802-5","article-title":"Replication kinetics and infectivity of SARS-CoV-2 variants of concern in common cell culture models","volume":"19","author":"Mautner","year":"2022","journal-title":"Virol. J."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1016\/j.cell.2021.03.028","article-title":"N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2","volume":"184","author":"McCallum","year":"2021","journal-title":"Cell"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.48550\/arXiv.1802.03426","article-title":"UMAP: uniform manifold approximation and projection for dimension reduction","author":"McInnes","year":"2018","journal-title":"arXiv"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e0297921","DOI":"10.1128\/mbio.02979-21","article-title":"The impact of evolving SARS-CoV-2 mutations and variants on COVID-19 vaccines","volume":"13","author":"McLean","year":"2022","journal-title":"mBio"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1038\/s41467-021-22166-4","article-title":"SARS-CoV-2 infection rewires host cell metabolism and is potentially susceptible to mTORC1 inhibition","volume":"12","author":"Mullen","year":"2021","journal-title":"Nat. Commun."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1016\/j.drudis.2022.04.001","article-title":"Repurposing drugs as COVID-19 therapies: a toxicity evaluation","volume":"27","author":"Ngan","year":"2022","journal-title":"A Toxic. Eval. Drug Discov. Today"},{"key":"B44","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1099\/jgv.0.001453","article-title":"SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology","volume":"101","author":"Ogando","year":"2020","journal-title":"J. Gen. Virol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2021.01.19.21249592","DOI":"10.1101\/2021.01.19.21249592","article-title":"The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera. medRxiv","author":"Rathnasinghe","year":"2021"},{"key":"B47","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.ccr.2011.04.004","article-title":"CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant","volume":"19","author":"Sakamoto","year":"2011","journal-title":"Cancer Cell"},{"key":"B48","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1146\/annurev-virology-100114-055218","article-title":"Continuous and discontinuous RNA synthesis in coronaviruses","volume":"2","author":"Sola","year":"2015","journal-title":"Coronaviruses Annu. Rev. Virol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ijid.2021.04.074","article-title":"Third wave of COVID-19 in Madrid, Spain","volume":"107","author":"Soriano","year":"","journal-title":"Int. J. Infect. Dis."},{"key":"B50","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ijid.2021.02.115","article-title":"Main differences between the first and second waves of COVID-19 in Madrid, Spain","volume":"105","author":"Soriano","year":"","journal-title":"Int. J. Infect. Dis."},{"key":"B51","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nrmicro775","article-title":"SARS--beginning to understand a new virus","volume":"1","author":"Stadler","year":"2003","journal-title":"Nat. Rev. Microbiol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1186\/s12859-021-04344-9","article-title":"CellProfiler 4: improvements in speed, utility and usability","volume":"22","author":"Stirling","year":"2021","journal-title":"BMC Bioinforma."},{"key":"B53","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41423-020-0400-4","article-title":"Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine","volume":"17","author":"Tai","year":"2020","journal-title":"Mol. Immunol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.devcel.2018.01.024","article-title":"Enteroid monolayers reveal an autonomous WNT and BMP circuit controlling intestinal epithelial growth and organization","volume":"44","author":"Thorne","year":"2018","journal-title":"Dev. Cell"},{"key":"B55","doi-asserted-by":"publisher","first-page":"106413","DOI":"10.1016\/j.isci.2023.106413","article-title":"Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages","volume":"26","author":"Touret","year":"2023","journal-title":"iScience"},{"key":"B56","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/s41591-021-01678-y","article-title":"An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies","volume":"28","author":"VanBlargan","year":"2022","journal-title":"Nat. Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"B58","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a neutralizing antibody cocktail, in outpatients with covid-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s11095-020-02851-7","article-title":"Repurposing of kinase inhibitors for treatment of COVID-19","volume":"37","author":"Weisberg","year":"2020","journal-title":"Pharm. Res."},{"key":"B60","doi-asserted-by":"publisher","first-page":"e01218","DOI":"10.1128\/JVI.01218-20","article-title":"Broad anti-coronavirus activity of food and drug administration-approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo","volume":"94","author":"Weston","year":"2020","journal-title":"J Virol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"591830","DOI":"10.3389\/fmed.2021.591830","article-title":"D-limonene is a potential monoterpene to inhibit PI3K\/Akt\/IKK-\u03b1\/NF-\u03baB p65 signaling pathway in coronavirus disease 2019 pulmonary fibrosis","volume":"8","author":"Yang","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","article-title":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia","volume":"367","author":"Zaki","year":"2012","journal-title":"Saudi Arab. N. Engl. J. Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41586-020-2548-6","article-title":"Potently neutralizing and protective human antibodies against SARS-CoV-2","volume":"584","author":"Zost","year":"","journal-title":"Nature"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1038\/s41591-020-0998-x","article-title":"Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein","volume":"26","author":"Zost","year":"","journal-title":"Nat. Med."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2025.1538934\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T01:25:27Z","timestamp":1747877127000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2025.1538934\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":64,"alternative-id":["10.3389\/fcell.2025.1538934"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2025.1538934","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.10.04.616743","asserted-by":"object"}]},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]},"article-number":"1538934"}}